Dianthus Therapeutics, Inc. /DE/ (DNTH) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $55.00K; Additional Paid in Capital, Common StockUSD $1.60B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.13M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $54.00K; Additional Paid in Capital, Common StockUSD $1.58B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-575.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $43.00K; Additional Paid in Capital, Common StockUSD $829.60M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $489.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $43.00K; Additional Paid in Capital, Common StockUSD $818.54M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $163.00K.
Dianthus Therapeutics, Inc. /DE/ Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $55.00K | $1.60B | $-2.13M | $-427.78M | $1.17B | 3 month · $11.90M | (m) |
| 2026-03-31 | $0.00 | $54.00K | $1.58B | $-575.00K | $-377.56M | $1.20B | 3 month · $10.60M | (m) |
| 2025-12-31 | $0.00 | $43.00K | $829.60M | $489.00K | $-336.73M | $493.40M | 12 month · $22.79M | (m) |
| 2025-09-30 | $0.00 | $43.00K | $818.54M | $163.00K | $-272.30M | $546.45M | 3 month · $5.79M | (m) |
| 2025-06-30 | $0.00 | $32.00K | $538.48M | $98.00K | $-235.53M | $303.08M | 3 month · $5.71M | (m) |
| 2025-03-31 | $0.00 | $32.00K | $532.21M | $270.00K | $-203.90M | $328.61M | 3 month · $5.32M | (m) |
| 2024-12-31 | $0.00 | $31.00K | $526.73M | $106.00K | $-174.39M | $352.48M | 12 month · $12.89M | (m) |
| 2024-09-30 | $0.00 | $29.00K | $483.14M | $681.00K | $-145.95M | $337.90M | 3 month · $3.84M | (m) |
| 2024-06-30 | $0.00 | $29.00K | $479.00M | $-37.00K | $-120.78M | $358.22M | 3 month · $3.10M | (m) |
| 2024-03-31 | $0.00 | $29.00K | $475.86M | $-27.00K | $-103.17M | $372.69M | 3 month · $2.04M | (m) |
| 2023-12-31 | $0.00 | $15.00K | $258.23M | $47.00K | $-89.42M | $168.87M | 12 month · $2.90M | (m) |
| 2023-09-30 | $0.00 | $15.00K | $257.23M | $-4.00K | $-78.86M | $178.38M | 3 month · $1.18M | (m) |
| 2023-06-30 | $0.00 | $61.00K | $509.03M | $-3.00K | $-434.48M | $-61.46M | 3 month · $462.00K 6 month · $922.00K | (m) |
| 2023-03-31 | $0.00 | $61.00K | $508.61M | $-16.00K | $-431.20M | $-50.82M | 3 month · $533.00K | (m) |
| 2022-12-31 | $0.00 | $0.00 | $1.66M | $-161.00K | $-45.87M | $-44.37M | 12 month · $1.52M | (m) |
| 2022-09-30 | $0.00 | $61.00K | $506.28M | $-462.00K | $-78.90M | $-34.75M | 3 month · $661.00K 9 month · $5.26M | (m) |
| 2022-06-30 | (m) | $59.00K | $502.01M | $-602.00K | $-365.79M | $-27.48M | 3 month · $279.00K 6 month · $3.75M | (m) |
| 2022-03-31 | (m) | $59.00K | $500.12M | $-469.00K | $-348.52M | $-22.07M | 3 month · $65.00K | (m) |
| 2021-12-31 | $0.00 | $0.00 | $143.00K | $0.00 | $-17.39M | $-17.25M | 12 month · $63.00K | (m) |
| 2021-09-30 | (m) | $59.00K | $495.90M | $1.00K | $-306.27M | $189.69M | 3 month · $3.80M 9 month · $8.12M | (m) |
| 2021-06-30 | (m) | $59.00K | $491.68M | $2.00K | $-288.85M | $202.89M | 3 month · $2.13M 6 month · $4.33M | (m) |
| 2021-03-31 | (m) | $49.00K | $400.92M | $9.00K | $-271.92M | $129.06M | 3 month · $2.19M | (m) |
| 2020-12-31 | (m) | $49.00K | $398.31M | $-23.00K | $-254.43M | $-4.20M | 12 month · $9.94M | (m) |
| 2020-09-30 | (m) | $48.00K | $394.74M | $39.00K | $-236.26M | $158.57M | 3 month · $2.37M 9 month · $7.61M | (m) |
| 2020-06-30 | (m) | $48.00K | $392.30M | $153.00K | $-218.59M | $173.91M | 3 month · $2.50M 6 month · $5.24M | (m) |
| 2020-03-31 | (m) | $39.00K | $324.50M | $363.00K | $-199.51M | $125.40M | 3 month · $2.74M | (m) |
| 2019-12-31 | (m) | $39.00K | $320.64M | $8.00K | $-179.50M | $141.19M | 12 month · $10.00M | (m) |
| 2019-09-30 | (m) | $39.00K | $317.67M | $83.00K | $-156.26M | $161.53M | 3 month · $2.76M 9 month · $7.94M | (m) |
| 2019-06-30 | (m) | $39.00K | $314.65M | $139.00K | $-135.27M | $179.56M | 3 month · $2.60M 6 month · $5.18M | (m) |
| 2019-03-31 | (m) | $34.00K | $251.49M | $41.00K | $-117.56M | $134.00M | 3 month · $2.58M | (m) |
| 2018-12-31 | (m) | $33.00K | $248.35M | $-8.00K | $-102.73M | $145.65M | 12 month · $10.70M | (m) |
| 2018-09-30 | (m) | $33.00K | $245.80M | (m) | $-86.05M | $159.78M | 3 month · $3.68M 9 month · $8.15M | 3 month · $123.00K |
| 2018-06-30 | (m) | $33.00K | $242.22M | (m) | $-70.03M | $172.22M | 3 month · $3.05M | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $-51.85M | 3 month · $1.43M | (m) |
| 2017-12-31 | (m) | $2.00K | $3.09M | (m) | $-45.21M | $-42.12M | 12 month · $2.26M | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | $-8.87M | 12 month · $662.00K | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | $-289.00K | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |